Essay fda guidelines

Submitted By mymdb
Words: 7361
Pages: 30
Open Document
GUIDELINES FOR PRECLINICAL AND CLINICAL EVALUATION
OF
AGENTS USED IN THE PREVENTION OR TREATMENT
OF
POSTMENOPAUSAL OSTEOPOROSIS

April, 1994

The FDA published Good Guidance Practices in February 1997.
This guidance was developed and issued prior to that date.

Division of Metabolic and Endocrine Drug Products
Food and Drug Administration
5600 Fishers Lane, HFD-510
Rockville, Maryland 20857-1706
(301)827-6430

1

GUIDELINES FOR PRECLINICAL AND CLINICAL EVALUATION
OF AGENTS USED IN THE PREVENTION OR TREATMENT
OF POSTMENOPAUSAL OSTEOPOROSIS

Table of Contents
Page
Preclinical Evaluation
I.
II.
III.
IV.
V.
VI.
VII.
VIII.

Introduction
Study Design
Animal Models
Biochemical Markers of Bone Turnover
Bone Mass/Density Measurement
Analysis of Bone Architecture/Histology
Biomechanical Testing of Bone Strength
Regulatory Aspects

2
3
3
4
4
5
5
5

Clinical Evaluation
I. Introduction
II. Clinical Studies
III. Study Duration and Assessment of Efficacy
IV. Procedure and Evaluation
V. Statistical Consideration
VI. Safety Testing
VII. Guide to FDA Action on NDA for Osteoporosis
VIII. Issues Related to Testing of
Combined Drug Regimens
IX. Research Priorities in
Postmenopausal Osteoporosis
X. References

6
8
11
16
18
20
21
22
22
23

2
GUIDELINES FOR PRECLINICAL AND CLINICAL EVALUATION OF AGENTS USED
IN THE PREVENTION OR TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
Preclinical Evaluation
I. Introduction
In addition to the toxicity studies required for all new drugs
(see CFR 312.23(8)), preclinical studies of bone quality should be performed for drugs to be used in the prevention and intervention of osteoporosis. For these guidelines, bone quality is considered to be comprised of the architecture, mass and strength of bone. These studies are warranted by instances in which bone density was not positively correlated with architecture and strength. Non-invasive techniques for assessing bone strength clinically (such as ultrasound) have not been adequately validated, but animal studies provide an opportunity to directly examine bone mass, architecture and strength. Thus, the primary objective of these studies is to demonstrate that long term treatment with a specific agent will not lead to deleterious effects on bone quality.
The proposed animal studies will permit early identification of drugs that result in abnormal architecture or in production of bone in which strength is not positively correlated with density and architecture. It may be possible to identify doses that control excessive bone resorption without suppressing osteoblast activity. These preclinical studies of bone quality might demonstrate efficacy in animals, but clinical efficacy must still be established.
Because no single animal species duplicates all the characteristics of human osteoporosis, it is felt that an examination of bone quality in two species is necessary to adequately investigate the effectiveness and safety of drugs for this indication. One study should be conducted in the ovariectomized rat model and the second in a non-rodent model
(i.e., larger, remodeling species) which will be left to the discretion of the sponsor although there is evidence that the dog may not be a good model1. Parameters to be monitored in these studies include biochemical markers of bone resorption and formation, histomorphometric analysis of bone architecture, measurement of bone density and biomechanical testing of bone strength. Histomorphometric, densitometric and biomechanical analyses should be performed on both long bones (femur and tibia) and lumbar vertebral bodies. Whenever possible, the parameters and techniques that will be used to demonstrate clinical efficacy should also be pursued in the preclinical studies. Further recommendations on these studies are detailed in the subsequent sections. 3
II. Study Design
Time of initiation of treatment in preclinical studies should be reflective of the clinical indication. Specifically, time of initiation of treatment will be different
Show More

Related Documents: Essay fda guidelines

Kendall Jones: Mallinckrodt Pharmaceuticals

Raleigh: FDA Regulatory…

Words 1461 - Pages 6

Helapharm's Signs Of A Successful Obesity Treatment

attain Food and Drug Administration (FDA) approval for launching the product in the U.S market. In a project of this cost and duration, it will be valuable to break down the overall project goals into goals for each major phase of the project. During the peptide discovery, the goal is to fInd a drug candidate. The major goal for the pre-clinical testing is to perform extensive tests to ensure the peptide is safe enough for human testing. Helapharm needs to obtain FDA approval for the Investigational…

Words 3290 - Pages 14

Fluoride Pros And Cons

should not be disseminating fluoride due to its ability to be toxic (Water.EPA.gov, 2015). The Food and Drug Administration (FDA) stated that fluoride is a prescription drug and not a mineral nutrient, which does not meet any safety or effectiveness guidelines, and hence, has prevented FDA approval of fluoride use (FDA.gov, 2015). Fluoride use became widespread before the FDA did thorough testing or even required testing. The American Dental Association recommends the use of fluoride, but has issued…

Words 294 - Pages 2

Prescription Medication Essay

still a smaller share relative to promotion aimed at influencing prescribers," said study author Julie M. Donohue, an assistant professor of health policy and management at the University Of Pittsburgh Graduate School Of Public Health. The U.S. FDA began allowing direct-to-consumer advertising of prescription drugs on television roughly 15 years ago. Since then, spots of Dorothy Hamill and Sally Field flogging Vioxx and Boniva, respectively, bouncing cartoon characters displaying the wonders…

Words 1006 - Pages 5

Essay about Antitrust Table notes

different price to likely gain a monopoly. Utah Pie Co. *Tie In sale/Tying Arrangement X** Where the sale of one product is predetermined that another product must also be purchased as well. Per se with a twist. Really, Rule of Reason. IBM Case Guidelines *Exclusive Dealing Contracts X An agreement in place in which the seller of product tells the buyer they can buy the seller’s competitor’s product. *Vertical Boycotts X Mergers X When businesses, either two or more, decide to…

Words 453 - Pages 2

Sports Nutrition Essay

Understand the significance of studying sports nutrition. 3. Identify the basic nutrients. 4. Explain how the body produces energy. 5. Define the Dietary Reference Intakes. 6. Define enriched and fortified foods. 7. Introduce the basic nutrition guidelines. 8. Explain how to read food labels. 9. Introduce factors that need to be considered when developing an individualized sports nutrition plan. 10. Discuss how sports nutrition knowledge can be applied. Chapter Outline I. What is sports nutrition…

Words 1864 - Pages 8

Persuasive Essay On Dietary Supplements

research to prevent diseases. Regulating dietary supplements have become a serious problem for the FDA. To help protect the American people, congress needs to take action by repealing the Dietary Supplement Health and Education Act (DSHEA). The old DSHEA should be replaced with legislation similar to the European Union’s Food Supplements Directive. By ensuring the public does not consume banned substances the FDA could potentially save hundreds of lives. Additionally, Pre-market approval…

Words 1280 - Pages 6

Marketing Herbal Products And Nutritional Supplements

any product can be quiet challenging if not done properly. There are many forces and environmental factors that a company must consider before doing so. Research must be conducted to ensure that all ingredients that are being used all meet strict FDA rules and that the approach to “selling” the item is not offensive to any particular group of consumers. By looking at statistics and taking polls is the most used way to see how consumers feel about that product. A major marketing environment force…

Words 1094 - Pages 5

Mutual Pharmaceutical Co., Inc. Inc. V. Bandatt

Pharmaceutical Co., Inc. v. Bartlett, 2013). In 2005, the respondent sued the petitioner in New Hampshire state court shortly after the FDA recommended a warning label change on NSAIDs to indicate toxic epidermal necrolysis as a possible side effect. The petitioner, Mutual Pharmaceutical, had the case removed to federal court based on the supremacy of federal law in FDA matters. In essence, federal law is superior to state law where the federal and state governments have competing statutes (Mutual Pharmaceutical…

Words 1688 - Pages 7

History Of Fitness On NBCNEWS

Interest, said his group has petitioned the Food and Drug Administration to drastically limit the use of trans fats and require restaurant menus to note foods containing trans-fat. He said FDA is still reviewing the petitions, "even though they agree its killing thousands of people a year." In January, the FDA began requiring package…

Words 2090 - Pages 9